{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:37:23Z","timestamp":1787801843199,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.josat.2025.209818","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T05:36:18Z","timestamp":1760938578000},"page":"209818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Gaps in buprenorphine access: Examining provider availability and treatment continuity"],"prefix":"10.1016","volume":"180","author":[{"given":"Abolfazl","family":"Sadeghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.josat.2025.209818_bb0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: a US nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value in Health"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jrh.12569","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"The Journal of Rural Health"},{"issue":"2","key":"10.1016\/j.josat.2025.209818_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/15360288.2022.2070691","article-title":"Comparing two databases to identify access to buprenorphine treatment for opioid use disorder","volume":"36","author":"Anyanwu","year":"2022","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.josat.2025.209818_bb6005","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/jamapsychiatry.2021.1969","article-title":"Contingency Management for Patients Receiving Medication for Opioid Use Disorder","volume":"78","author":"Bol\u00edvar","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"16","key":"10.1016\/j.josat.2025.209818_bb0020","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1056\/NEJMc2312906","article-title":"Buprenorphine dispensing after elimination of the waiver requirement","volume":"390","author":"Chua","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.josat.2025.209818_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the US opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2025.209818_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c5475","article-title":"Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database","volume":"341","author":"Cornish","year":"2010","journal-title":"Bmj"},{"key":"10.1016\/j.josat.2025.209818_bb0035","series-title":"Quality ID #468 (NQF 3175): Continuity of pharmacotherapy for opioid use disorder","author":"Department for Health and Human Services. Centers for Medicare and Medicaid Services","year":"2019"},{"key":"10.1016\/j.josat.2025.209818_bb0040","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7325a1","article-title":"Treatment for opioid use disorder: Population estimates \u2014 United States, 2022","volume":"73","author":"Dowell","year":"2024","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0045","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.sapharm.2020.06.003","article-title":"Impact of COVID-19 related policy changes on filling of opioid and benzodiazepine medications","volume":"17","author":"Downs","year":"2021","journal-title":"Research in Social and Administrative Pharmacy"},{"key":"10.1016\/j.josat.2025.209818_bb0050","series-title":"Expansion of buprenorphine treatment via telemedicine encounter","author":"Drug Enforcement Administration","year":"2025"},{"issue":"8","key":"10.1016\/j.josat.2025.209818_bb0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14045","article-title":"Monthly patient volumes of buprenorphine-waivered clinicians in the US","volume":"3","author":"Duncan","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209818_bb0060","unstructured":"Economic Research Service. (n.d.). Rural-urban continuum codes\u2014Documentation. Retrieved May 12, 2025, from https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes\/documentation."},{"key":"10.1016\/j.josat.2025.209818_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209280","article-title":"Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services","volume":"160","author":"Franz","year":"2024","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2025.209818_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.029","article-title":"US trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018","volume":"204","author":"Ghertner","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/add.15998","article-title":"The association between buprenorphine treatment duration and mortality: A multi-site cohort study of people who discontinued treatment","volume":"118","author":"Glanz","year":"2023","journal-title":"Addiction (Abingdon, England)"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jrh.12785","article-title":"Medication treatment for opioid use disorder among rural primary care patients","volume":"40","author":"Hser","year":"2024","journal-title":"The Journal of Rural Health"},{"issue":"3","key":"10.1016\/j.josat.2025.209818_bb0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jrh.12570","article-title":"An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic","volume":"37","author":"Hughes","year":"2021","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.josat.2025.209818_bb0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jsat.2018.07.008","article-title":"Comparison between buprenorphine provider availability and opioid deaths among US counties","volume":"93","author":"Jones","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"9","key":"10.1016\/j.josat.2025.209818_bb0095","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s11606-022-07975-7","article-title":"Increasing access to buprenorphine for opioid use disorder in primary care: An assessment of provider incentives","volume":"38","author":"Kelley","year":"2023","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2025.209818_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109081","article-title":"Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States","volume":"228","author":"Kiang","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209818_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108131","article-title":"Geographic proximity to buprenorphine treatment providers in the US","volume":"213","author":"Langabeer","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209818_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112628","article-title":"The opioid epidemic in rural communities: Can telehealth increase access to medications for opioid use disorder and offset barriers to care?","volume":"271","author":"Meyers","year":"2025","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0115","doi-asserted-by":"crossref","first-page":"2270632","DOI":"10.1080\/17445647.2023.2270632","article-title":"Race, rurality and geographic accessibility to medication for opioid use disorder in the US","volume":"19","author":"Mitchell","year":"2023","journal-title":"Journal of Maps"},{"issue":"9","key":"10.1016\/j.josat.2025.209818_bb0120","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1360-0443.2012.03870.x","article-title":"Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study","volume":"107","author":"Nosyk","year":"2012","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.josat.2025.209818_bb0125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses","volume":"62","author":"Ostrach","year":"2022","journal-title":"Journal of the American Pharmacists Association"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb6010","article-title":"A multilevel analysis of changing telehealth availability in opioid use disorder treatment settings: Conditional effects of rurality, the number and types of medication for opioid use disorder available, and time, US, 2016-2023","volume":"41","author":"Pro","year":"2025","journal-title":"The Journal of rural health\u202f: official journal of the American Rural Health Association and the National Rural Health Care Association"},{"issue":"8","key":"10.1016\/j.josat.2025.209818_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.josat.2025.209818_bb0135","series-title":"Mainstreaming Addiction Treatment Act of 2021","author":"S.445","year":"2021"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0140","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/08897077.2021.1986882","article-title":"A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid","volume":"43","author":"Saloner","year":"2022","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.josat.2025.209818_bb0145","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amepre.2023.01.037","article-title":"Buprenorphine after nonfatal opioid overdose: reduced mortality risk in medicare disability beneficiaries","volume":"65","author":"Samples","year":"2023","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.josat.2025.209818_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108774","article-title":"Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes","volume":"139","author":"Samples","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209818_bb0160","author":"Sen. Bennet"},{"issue":"12","key":"10.1016\/j.josat.2025.209818_bb0165","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2025.209818_bb0170","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"Bmj"},{"key":"10.1016\/j.josat.2025.209818_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u201cRed Flags\u201d and \u201cRed Tape\u201d: Telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2025.209818_bb6015","author":"Torrez"},{"key":"10.1016\/j.josat.2025.209818_bb0180","author":"Varisco"},{"key":"10.1016\/j.josat.2025.209818_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108073","article-title":"Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder","volume":"117","author":"Varisco","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2025.209818_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2021.04.014","article-title":"Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine","author":"Varisco","year":"2021","journal-title":"Journal of the American Pharmacists Association"},{"issue":"6","key":"10.1016\/j.josat.2025.209818_bb0195","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: Buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids","volume":"17","author":"Weimer","year":"2023","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.josat.2025.209818_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18487","article-title":"Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder","volume":"4","author":"Weintraub","year":"2021","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1016\/j.josat.2025.209818_bb0205","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1007\/s11606-024-08898-1","article-title":"Integrating buprenorphine for opioid use disorder into rural, primary care settings","volume":"39","author":"Wyse","year":"2024","journal-title":"Journal of General Internal Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:54:30Z","timestamp":1764712470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":43,"alternative-id":["S2949875925001973"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209818","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaps in buprenorphine access: Examining provider availability and treatment continuity","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209818"}}